Læknablaðið - des. 2018, Blaðsíða 16

548 LÆKNAblaðið 2018/104
Y F I R L I T S G R E I N
1. Galambos JT, Hersh T, Schroder S, Wenger J. Loperamide:
A New Antidiarrheal Agent in the Treatment of Chronic
Diarrhea. Gastroenterology 1976; 70: 1026-9.
2. Read M, Read NW, Barber DC, Duthie HL. Effects of
loperamide on anal sphincter function in patients compla-
ining of chronic diarrhea with fecal incontinence and
urgency. Dig Dis Sci 1982; 27: 807-14.
3. Baker DE. Loperamide: a pharmacological review. Rev
Gastroenterol Dis 2007; 7: S11-S18.
4. Jaffe JH, Kanzler M, Green J. Abuse potential of loper-
amide. Clin Pharmacol Therap 1980; 28: 812-9.
5. Lists of: Scheduling Actions, Controlled Substances,
Regulated Chemicals. U.S. Department of Justice, DEA,
Diversion Control Division. deadiversion.usdoj.gov/
schedules/orangebook/orangebook.pdf - mars 2018.
6. World Health Organization: List of Essential Medicines.
who.int/medicines/publications/pharmacopoeia - sótt í
janúar 2018.
7. Hurtado-Torres G.F, Sandoval-Munro RL. An Additional
Clinical Scenario of Risk for Loperamide Cardiac-Induced
Toxicity. Am J Med 2016; 129: e33.
8. US Food & Drug Administration: FDA warns about
serious heart problems with high doses of the antidiarr-
heal medicine loperamide (Imodium), including from
abuse and misuse. (2016). fda.gov/Drugs/DrugSafety/
ucm504617.htm - janúar 2018.
9. Swank KA, Wu E, Kortepeter C, McAninch J, Levin RL.
Adverse event detection using the FDA post-marketing
drug safety surveillance system: Cardiotoxicity associated
with loperamide abuse and misuse. J Am Pharmac Ass
2017; 57: S63-S67.
10. Lyfjaupplýsingar - Sérlyfjaskrá. serlyfjaskra.is/FileRepos/
a300dedf-b189-e711-80d5-ce1550b700f3/Imodium-SmPC.
pdf – janúar 2018.
11. Niemi M, Tornio A, Pasanen MK, Fredrikson H,
Neuvonen PJ, Backman JT. Itraconazole, gemfibrozil
and their combination markedly raise the plasma
concentrations of loperamide. Eur J Clin Pharmacol 2006;
62: 463-72.
12. Ericsson CD, Johnson PC. Safety and efficacy of loper-
amide. Am J Med 1990; 88: 10S-14S.
13. Heel RC, Brogden RN, Speight TM, Avery GS. Loperamide:
a review of its pharmacological properties and therapeutic
efficacy in diarrhoea. Drugs 1978; 15: 33-52.
14. Montesinos RN, Moulari B, Gromand J, Beduneau
A, Lamprecht A, Pellequer Y. Coadministration of
p-glycoprotein modulators on loperamide pharmaco-
kinetics and brain distribution. Drug Metabol Disp 2014;
42: 700-6.
15. Bishop-Freeman SC, Feaster MS, Beal J, Miller A,
Hargrove RL, Brower JO, et al. Loperamide-related deaths
in North Carolina. J Analyt Toxicol 2016; 40: 677-86.
16. Schinkel A.H. P-Glycoprotein, a gatekeeper in the blood-
brain barrier. Adv Drug Delivery Rev 1999; 36: 179-94.
17. Sartor LL, Bentjen SA, Trepanier L, Mealey KL.
Loperamide toxicity in a collie with the MDR1 mutation
associated with ivermectin sensitivity. J Veter Int Med
2004; 18: 117-8.
18. Schinkel AH, Wagenaar E, Mol CA, van Deemter L.
P-glycoprotein in the blood-brain barrier of mice influ-
ences the brain penetration and pharmacological activity
of many drugs. J Clin Investig 1996; 97: 2517-24.
19. Yanagita T, Miyasato K, Sato J. Dependence potential
of loperamide studied in rhesus monkeys. NIDA Res
Monograph 1979; 27: 106-13.
20. Tan-No K, Niijima F, Nakagawasai O, Sato T, Satoh S,
Tadano T. Development of tolerance to the inhibitory
effect of loperamide on gastrointestinal transit in mice.
European J Pharmaceut Sci 2003; 20: 357-63.
21. Korey A, Zilm DH, Sellers E.M. Dependence liability
of two antidiarrheals, nufenoxole and loperamide. Clin
Pharmacol Therapeut 1980; 27: 659-64.
22. Daniulaityte R, Carlson R, Falck R, Cameron D, Perera S,
Chen L, et al. ‘I just wanted to tell you that loperamide
WILL WORK’ : A web-based study of extra-medical use of
loperamide. Drug Alcohol Depend 2013; 130: 241-4.
23. Marraffa JM, Holland MG, Sullivan RW, Morgan BW,
Oakes JA, Wiegand TJ, et al. Cardiac conduction distur-
bance after loperamide abuse. Clin Toxicol 2014; 52: 952-7.
24. Wightman RS, Hoffman RS, Howland MA, Rice B, Biary
R, Lugassy D. Not your regular high cardiac dysrhythmias
caused by loperamide. Clin Toxicol 2016; 54: 454-8.
25. Mancano MA. High-Dose Loperamide Abuse Inducing
Life-Threatening Cardiac Arrhythmias; Topiramate-
Induced Diarrhea in a Breastfed Infant; Danazol-
Induced Stevens–Johnson Syndrome; Asenapine-Induced
Myasthenic Syndrome; Black Hairy Tongue Due to
Linezolid; Adalimumab-I. Hospital Pharmacy 2015; 50:
351-5.
26. Enakpene EO, Riaz I.B, Shirazi FM, Raz Y, Indik JH. The
long QT teaser: Loperamide abuse. Am J Med 2015; 128:
1083-6.
27. Marzec L.N, Katz DF, Peterson PN. Torsade de Pointes
Associated with High-dose Loperamide Ingestion. J Innov
Cardiac Rhythm Manage 2015; 6: 1897-9.
28. Vithalani ND, Heron C, Rao RE, Cardell AF, Stephens
MB. Dysrhythmias with Loperamide Used for Opioid
Withdrawal. J Am Board Fam Med 2017; 30: 832-4.
29. Larsen TR, McMunn J, Ahmad H, AlMahameed ST.
Ventricular Tachycardia Triggered by Loperamide and
Famotidine Abuse. Drug Safety - Case Rep 2018; 5: 11.
30. Sun C, Brice JA, Clark RF. Brugada-Type Pattern
on Electrocardiogram Associated with High-Dose
Loperamide Abuse. J Emerg Med 2018; 54: 484-6.
31. Rasla S, St Amand A, Garas MK, El Meligy A, Minami T.
Unexpected Serious Cardiac Arrhythmias in the Setting of
Loperamide Abuse. Rhode Island Med J 2017; 100: 33-6.
32. Spinner HL, Lonardo NW, Mulamalla R, Stehlik J.
Ventricular tachycardia associated with high-dose chronic
loperamide use. Pharmacothera 2015; 35: 234-8.
33. Eggleston W, Clark KH, Marraffa JM. Loperamide Abuse
Associated With Cardiac Dysrhythmia and Death. Ann
Emerg Med 2017; 69: 83-6.
34. Upadhyay A, Bodar V, Malekzadegan M, Singh S,
Frumkin W, Mangla A, et al. Loperamide Induced Life
Threatening Ventricular Arrhythmia. Case Rep Cardiol
2016; 2016: 1-3.
35. MacDonald R, Heiner J, Villarreal J, Strote J. Loperamide
dependence and abuse. BMJ Case Rep 2015; 2015: 2-4.
36. Smith N.A, Sehring M, Chambers J. Loperamide abuse
and cardiotoxicity. J Comm Hosp Int Med Perspect 2017;
7: 275.
37. Leo RJ, Ghazi MA, Jaziri KS. Methadone Management of
Withdrawal Associated with Loperamide-related Opioid
Use Disorder. J Add Med 2017; 11: 402-4.
38. Di Rosa E, Di Rosa AE. Loperamide overdose-induced
catatonia: potential role of brain opioid system and
P-glycoprotein. Acta Neuropsychiatr 2014; 26: 58-60.
39. Mittal A, Sangani R, Cerone M, Stansbury R. Seizur-Like
Activity and Recurrent Cardiac Arrests in a Healthy
24-Year-Old: Loperamide Abuse; a Case Report and
Literature Review. Chest 2017; 152: A386.
40. Napier C, Gan EH, Pearce SHS. Loperamide-induced
hypopituitarism. BMJ Case Rep 2016; 2016: 1-3.
41. Patel KM, Shah S, Subedi D. Takotsubo-Like
Cardiomyopathy After Loperamide Overdose. Am J
Therapeut 2017; 3: 1-3.
42. Vaughn P, Solik M, Bagga S, Padanilam BJ. Electro-
cardio graphic Abnormalities, Malignant Ventricular
Arrhythmias, and Cardiomyopathy Associated With
Loperamide Abuse. J Cardiovasc Electrophysiol 2016; 27:
1230-3.
43. Zarghami M, Rezapour M. Loperamide Dependency : A
Case Report. Add Health 2017; 9: 59-63.
44. Dierksen J, Gonsoulin M, Walterscheid JP. Poor Manʼs
Methadone. Am J Forensic Med Pathol 2015; 36: 268-70.
45. Caro MA, Shah SA, Jerry JM, Tesar GE, Khawam EA.
Loperamide Abuse and Life-Threatening Arrhythmias: A
Case Report and Literature Review. Psychosom 2017; 58:
441-5.
46. Riaz IB, Khan MS, Kamal MU, Sipra QR, Riaz A, Zahid U,
et al. Cardiac Dysrhythmias Associated With Substitutive
Use of Loperamide: A Systematic Review. Am J Therapeut
2017; 13: 1-13.
47. Hill MA, Greason FC. Loperamide dependence. J Clin
Psychiatr 1992; 53: 450.
48. Borron SW, Watts S.H, Tull J, Baeza S, Diebold S, Barrow
A, et al. Intentional Misuse and Abuse of Loperamide: A
New Look at a Drug with ‘Low Abuse Potential’. J Emerg
Med 2017; 53: 73-84.
49. Jóhannsson M, Aradóttir AB, Guðmundsson LS, Einarsson
ÓB. Frá Embætti landlæknis 14. pistill. Ávísanir á ópíóíða
og alvarleg fíkn. Læknablaðið 2016; 102: 362.
50. Leiðbeiningar um góða starfshætti lækna við ávísun lyfja.
landlaeknir.is/um-embaettid/greinar/grein/item31883/
leidbeiningar-um-goda-starfshaetti-laekna-vid-avisun-
lyfja – mars 2018.
51. Takmörkun á ávísun nokkurra eftirritunarskyldra lyfja.
lyfjastofnun.is/utgefid-efni/frettir/takmorkun-a-avisun-
-nokkurra-eftirritunarskyldra-lyfja – mars 2018.
52. Helstu breytingar í ávísunum ávanabindandi lyfja frá 2016
til 2017 á Íslandi. landlaeknir.is/um-embaettid/frettir/frett/
item33942/helstu-breytingar-i-avisunum-avanabindandi-
-lyfja- fra-2016-til-2017-a-islandi – mars 2018.
53. Ópíóíðafíklum fjölgað um 68% mbl.is/frettir/inn-
lent/2018/04/19/opioidafiklum_fjolgad_um_68_prosent/
– apríl 2018.
54. Going Through Loperamide Withdrawal - Tips on
Surviving the Addiction. madmargaret.wordpress.
com/2014/01/15/going-through-loperamide-withdrawal-
tips-on-surviving-the- addiction/ – mars 2018.
55. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui
J, Meshesha LZ, et al. Buprenorphine Treatment for
Hospitalized, Opioid-Dependent Patients. JAMA Int Med
2014; 174: 1369.
56. Kleber HD. Pharmacologic treatments for opioid
dependence: detoxification and maintenance options.
Dialog Clin Neurosci 2007; 9: 455-70.
57. Fareed A, Patil D, Scheinberg K, Blackinton GR,
Vayalapalli S, Casarella J, et al. Comparison of QTc
Interval Prolongation for Patients in Methadone Versus
Buprenorphine Maintenance Treatment: A 5-Year Follow-
Up. J Add Dis 2013; 32: 244-51.
58. Egglestone W, Nacca N, Marraffa JM. Buprenorphine
Induced Acute Precipitated Withdrawal in the Setting of
Loperamide Abuse. Conference: Clin Toxicol 2015; 53.
59. ÁÁ - Ársskýrsla 2016. saa.is/wp-content/uploads/2017/02/
Ársrit_skýrsla_18022017_an_crop.pdf –apríl 2018.
60. Rúnarsdóttir V. Upplýsingar gefnar höfundum í tölvu-
pósti, mars 2018.
Heimildalistinn er birtur í heild sinni á netinu.
Heimildir
Barst til blaðsins 9. september 2018, samþykkt til birtingar 12. nóvember 2018.
Frá
fyrsta
bita*
hraðvirkt aspartinsúlín
Vistor hf. – umboðsaðili á Íslandi
Hörgatúni 2 · 210 Garðabæ
novo@vistor.is ( 535 7000
Pantone litir:
Hjarta: Rautt: 200C
Letur: Grátt: 424C
CMYK litir:
Hjarta: Cyan: 10, Magenta: 100, Yellow: 100, Svart: 20
Letur: Cyan: 10, Magenta: 10, Yellow: 10, Svart: 60
Hraðari insúlínsvörun við máltíðir
Fiasp®
Samanborið við NovoRapid®1
Kostir Fiasp fyrir fullorðna sjúklinga með sykursýki:
Vel þekkt
Hraðvirkari formúla NovoRapid, þegar skipt er um
meðferð má reikna með 1:1 einingu1,4
Sveigjanleiki
Möguleiki á sveigjanleika með tilliti til tímasetningar
lyfjagjafar þegar þörf krefur1,3‡§
Staðfest verkun
Lækkar HbA1c og blóðsykur eftir máltíð án aukinnar
tíðni blóðsykursfalla samanborið við NovoRapid1,3
Fljótvirkara
Berst tvisvar sinnum hraðar í
blóðrásina samanborið við NovoRapid1,2†
* Gefið undir húð rétt áður en máltíð hefst (0–2 mínútum fyrir).1
† Staðfest á sjúklingum með sykursýki af tegund 1 samanborið við NovoRapid.
‡ Fiasp má gefa 2 mínútum fyrir máltíð og allt að 20 mínútum eftir að máltíð hefst.
§ Samanborið við NovoRapid gefið við máltíð. Grundvallað á upplýsingum úr Onset® 1, rannsókn á fullorðnum sjúklingum með sykursýki af tegund 1.3
Heimildir: 1. Samantekt á eiginleikum lyfs fyrir Fiasp, www.serlyfjaskra.is. 2. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic
and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmaco. doi:10.1007/s40262-017-0514-8. 3. Russell-Jones D, Bode BW, De Block C, et al. Fast-acting
insulin aspart improves glycemic control in basal–bolus treatment for type 1 diabetes: results of a 26-week multicenter, active controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care.
doi:10.2337/dc16-1771.t, randomized, parallel-group trial (onset 1). Diabetes Care. doi:10.2337/dc16-1771. 4. Meah F, Juneja R. Insulin tactics in type 2 diabetes. Med Clin N Am. 2015;99:157-186.
Fiasp 100 einingar/ml stungulyf, lausn í rörlykju
Heiti virkra efna: Ein rörlykja inniheldur 300 einingar aspartinsúlín í 3 ml af lausn. 1 ml af lausn
inniheldur 100 einingar aspartinsúlín (jafngildir 3,5 mg). Ábendingar: Meðferð við sykursýki
hjá fullorðnum. Frábendingar: Ofnæmi fyrir virka efninu eða einhverju hjálparefnanna.
Markaðsleyfishafi: Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Danmörk. Nálgast
má upplýsingar um lyfið, fylgiseðil þess og gildandi samantekt á eiginleikum lyfs á vef
Lyfjastofnunar, www.serlyfjaskra.is.
Fiasp 100 einingar/ml stungulyf, lausn í áfylltum lyfjapenna
Heiti virkra efna: Einn áfylltur lyfjapenni inniheldur 300 einingar aspartinsúlín í 3 ml lausn.
1 ml af lausn inniheldur 100 einingar aspartinsúlín (jafngildir 3,5 mg). Ábendingar: Meðferð
við sykursýki hjá fullorðnum. Frábendingar: Ofnæmi fyrir virka efninu eða einhverju hjálpar-
efnanna. Markaðsleyfishafi: Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Danmörk.
Nálgast má upplýsingar um lyfið, fylgiseðil þess og gildandi samantekt á eiginleikum lyfs
á vef Lyfjastofnunar, www.serlyfjaskra.is.
Fi
as
p®
o
g
N
ov
oR
ap
id
®
e
ru
s
kr
ás
et
t
vö
ru
m
er
ki
í
ei
gu
N
ov
o
N
or
di
sk
A
/S
· I
S/
D
K
/F
A
/1
21
7/
03
24
· 1
6.
o
kt
ób
er
2
01
8